Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 5 years by 5.13% on an annualized basis producing an average annual return of 19.08%. Currently, Netflix has a market capitalization of $514.16 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 5 years ago, it would be worth $235.27 today based on a price of $1210.00 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1756847714_0.png" alt="comp_fig" />

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Netflix 5 Years Ago Would Be Worth This Much Today

<h3>Gainers</h3>
<ul>
<li>HWH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) shares rose 11.2% to $5.25 during Tuesday's after-market session. The market value of their outstanding shares is at $9.3 million. </li>
<li>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) shares moved upwards by 8.39% to $229.09. The company's market cap stands at $2.5 trillion. </li>
<li>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) shares moved upwards by 8.1% to $229.17. The company's market cap stands at $2.5 trillion. </li>
<li>Mega Matrix (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MPU#AMEX">MPU</a>) shares rose 4.92% to $2.13. The market value of their outstanding shares is at $124.5 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) stock rose 4.73% to $3.74. The market value of their outstanding shares is at $5.4 million. </li>
<li>K Wave Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) stock moved upwards by 2.81% to $2.19. The market value of their outstanding shares is at $109.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fangdd Network Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares decreased by 6.8% to $2.44 during Tuesday's after-market session. The company's market cap stands at $9.3 million. </li>
<li>PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>) stock declined by 5.07% to $1.5. The company's market cap stands at $41.7 million. </li>
<li>Intelligent Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) shares declined by 4.85% to $0.57. The company's market cap stands at $16.0 million. </li>
<li>Kartoon Studios (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOON#AMEX">TOON</a>) shares fell 3.67% to $0.78. The company's market cap stands at $37.9 million. </li>
<li>Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) stock decreased by 3.45% to $8.41. The company's market cap stands at $148.9 million. </li>
<li>Sound Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOGP#NASDAQ">SOGP</a>) shares decreased by 2.93% to $21.23. The market value of their outstanding shares is at $63.4 million. The company's, H1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Communication Services Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Propanc Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPCB#NASDAQ">PPCB</a>) stock rose 7.0% to $2.92 during Tuesday's after-market session. The market value of their outstanding shares is at $38.0 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares moved upwards by 6.9% to $1.85. The market value of their outstanding shares is at $68.0 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock increased by 6.3% to $3.54. The company's market cap stands at $122.9 million. </li>
<li>Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) shares rose 6.12% to $21.5. The company's market cap stands at $923.4 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) stock increased by 5.99% to $1.68. The market value of their outstanding shares is at $230.3 million. </li>
<li>ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares increased by 5.82% to $1.09. The market value of their outstanding shares is at $62.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares decreased by 9.1% to $30.2 during Tuesday's after-market session. The company's market cap stands at $5.1 billion. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares fell 6.72% to $1.18. The company's market cap stands at $15.3 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock declined by 6.33% to $0.85. The company's market cap stands at $9.5 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock declined by 5.64% to $4.69. The company's market cap stands at $2.9 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares fell 5.5% to $0.42. The company's market cap stands at $8.9 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares declined by 5.48% to $1.9. The company's market cap stands at $170.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares moved upwards by 28.1% to $4.28 during Tuesday's after-market session. The company's market cap stands at $9.0 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 18.9% to $0.48. The market value of their outstanding shares is at $5.3 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares rose 18.12% to $8.21. The company's market cap stands at $16.7 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) stock rose 5.93% to $1.25. The company's market cap stands at $13.6 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock increased by 5.24% to $0.57. The company's market cap stands at $7.1 million. </li>
<li>Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) stock increased by 4.95% to $2.54. The market value of their outstanding shares is at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) stock decreased by 7.1% to $0.58 during Tuesday's after-market session. The company's market cap stands at $8.3 million. </li>
<li>Planet Image Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) stock decreased by 6.67% to $1.26. The market value of their outstanding shares is at $66.8 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock fell 6.42% to $0.91. The company's market cap stands at $22.4 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares decreased by 6.09% to $0.42. The market value of their outstanding shares is at $11.8 million. </li>
<li>Ten-League International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIH#NASDAQ">TLIH</a>) shares fell 5.71% to $0.54. The company's market cap stands at $16.1 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares declined by 5.27% to $3.06. The market value of their outstanding shares is at $54.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) shares increased by 5.8% to $0.34 during Tuesday's after-market session. The market value of their outstanding shares is at $10.1 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares moved upwards by 5.16% to $0.26. The company's market cap stands at $192.5 million. </li>
<li>Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) stock increased by 4.86% to $21.56. The market value of their outstanding shares is at $401.9 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock rose 4.25% to $1.96. The market value of their outstanding shares is at $24.8 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock moved upwards by 4.12% to $0.71. The market value of their outstanding shares is at $21.4 million. </li>
<li>Universal Safety Products (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUU#AMEX">UUU</a>) stock increased by 3.97% to $6.01. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares fell 4.7% to $0.47 during Tuesday's after-market session. The market value of their outstanding shares is at $14.2 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares fell 4.57% to $3.76. The market value of their outstanding shares is at $5.1 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) stock decreased by 4.12% to $127.1. The company's market cap stands at $9.2 billion. </li>
<li>Wearable Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) stock declined by 4.09% to $1.06. The company's market cap stands at $2.4 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares fell 3.18% to $1.51. The company's market cap stands at $6.5 million. </li>
<li>RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) shares fell 3.15% to $6.15. The company's market cap stands at $74.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Information Technology Stocks Moving In Tuesday's After-Market Session

The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed the first day of September down 0.7%. Investors now start the month wondering if the "September Effect" is here and the market will once again post negative returns for the <a href="https://www.benzinga.com/24/09/40676774/september-market-seasonality-why-this-month-is-historically-the-toughest-for-investors">worst month of the year.</a>



<h2 class="wp-block-heading">September Declines</h2>



Market experts and analysts often highlight seasonality for investors, with some sectors and the overall stock market showing patterns of positive or negative returns depending on the <a href="https://www.benzinga.com/markets/market-summary/25/09/47438659/sp500-september-seasonality-worst-stocks">time of year.</a>



Freedom Capital Markets Chief Market Strategist Jay Woods highlighted the September Effect of the stock market in his weekly <a href="https://dashboard.mailerlite.com/forms/430322/151045652250363569/share">newsletter</a>.



"September is the worst month for the market, period," Woods said. "Going back to 1980, it's the only month that is negative on average."



The S&amp;P 500 has been lower in four of the last five years, posting an average loss of 4.2%, Woods adds.



Here's a look at the monthly average returns since 1980, as reported by Freedom Capital Markets:



<ul class="wp-block-list">
<li>January: +0.9%</li>



<li>February: +0.2%</li>



<li>March: +1.1%</li>



<li>April: +1.5%</li>



<li>May: +1.1%</li>



<li>June: +0.4%</li>



<li>July: +1.3%</li>



<li>August: +0.1%</li>



<li>September: -0.9%</li>



<li>October: +1.2%</li>



<li>November: +2.1%</li>



<li>December: +1.2%</li>
</ul>



"I'm not quite sure Green Day was referring to the stock market when they wrote ‘Wake Me Up When September Ends,' but given its historical results the song is apropos," Woods said.



Woods said there are theories as to why the market sells off in September, but no real answers. Among the potential reasons include portfolio readjustments, taking gains, taking losses for tax purposes, coming back from summer vacation or selling assets to pay for education.



"Whatever the real reasons, it's a statistical fact that for nearly 100 years, going back to 1928, it is the worst performing month of the year with only a 55% chance that it finishes higher during that time."



Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/09/47453570/exclusive-augusts-20-most-searched-tickers-on-benzinga-pro-where-do-opendoor-palantir-bitmine-immersion-apple-stock-rank">EXCLUSIVE: August&#8217;s 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?</a>



<h2 class="wp-block-heading">Why It&#8217;s Important </h2>



The SPDR S&amp;P 500 ETF Trust is currently up 9.5% year-to-date, with new all-time highs set last week, as the S&amp;P 500 Index hit the 6,500 level for the first time.



In fact, the S&amp;P 500 hit five new all-time highs during the month of August.



Woods said August was the fourth straight month with a positive return for the S&amp;P 500. Here's a look at the current returns of the SPY for each month this year, as shared by Ycharts.



<ul class="wp-block-list">
<li>January: +2.87%</li>



<li>February: -1.4%</li>



<li>March: -5.8%</li>



<li>April: -0.8%</li>



<li>May: +6.2%</li>



<li>June: +5.0%</li>



<li>July: +2.2%</li>
</ul>



The last four months have had positive returns and helped to offset a poor three-month stretch from February through April.



The S&amp;P 500 is now positive in five of the eight completed months in 2025, with four months remaining.



September remains a key wild card with seasonal weakness and the upcoming Federal Reserve meeting that could see a rate cut and the market reaction.



If the market can make it out of September with a gain or slight loss, it could be smooth sailing the rest of the year. October and December are tied for the third-best month returns on average since 1980, with November ranking as the best monthly returns on average since 1980.



<h2 class="wp-block-heading">SPY Price Action </h2>



The SPDR S&amp;P 500 ETF Trust was down 0.7% to $640.27 on Tuesday versus a 52-week trading range of $481.81 to $649.62. The ETF is up 9.5% year-to-date in 2025.



Read Next: 



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/08/47369422/wall-street-market-outlook-stocks-vix-september-seasonality-nvidia-earnings">Wall Street Has No Fear—But A Shocking Selloff Could Be Lurking</a></li>
</ul>



Image: Shutterstock

September Effect Starts Month With Decline After August Saw 5 New All-Time Highs: 'Worst Month For The Market, Period'

Looking into the current session, Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) shares are trading at $76.80, after a 2.50% drop. Over the past month, the stock decreased by 20.04%, but over the past year, it actually spiked by 0.07%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846886_0.png" alt="Past Year Chart" />
<h3>Comparing Fortinet P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Fortinet has a lower P/E than the aggregate P/E of 109.16 of the Software industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846886_1.png" alt="Guage" />
In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

A Look Into Fortinet Inc's Price Over Earnings

Ratings for Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $333.33, a high estimate of $380.00, and a low estimate of $285.00. This current average has increased by 9.59% from the previous average price target of $304.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846872_0.png" alt="price target chart" />

<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Acuity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Christopher Snyder</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$335.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acuity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acuity compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Acuity's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acuity's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AYI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Acuity analyst ratings.</a>
<h2>Get to Know Acuity Better</h2>
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
<h3>Financial Insights: Acuity</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Acuity displayed positive results in 3M. As of 31 May, 2025, the company achieved a solid revenue growth rate of approximately 21.74%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Acuity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.35%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acuity's ROE excels beyond industry benchmarks, reaching 3.86%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acuity's ROA excels beyond industry benchmarks, reaching 2.13%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.42, Acuity adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Acuity

6 analysts have expressed a variety of opinions on Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts have recently evaluated Deere and provided 12-month price targets. The average target is $548.5, accompanied by a high estimate of $602.00 and a low estimate of $488.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.73%. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846863_0.png" alt="price target chart" />

<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Deere by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$495.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Michael Shlisky</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$580.00</td>
<td>$595.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$488.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$602.00</td>
<td>$619.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$566.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$560.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Deere. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Deere compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Deere's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Deere's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Deere analyst ratings.</a>
<h2>Get to Know Deere Better</h2>
Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production &amp; precision agriculture (PPA), small agriculture &amp; turf (SAT), construction &amp; forestry (CF), and financial services (FS), its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere financial provides retail financing for machinery to its customers and wholesale financing for dealers.
<h3>Deere: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3M period, Deere faced challenges, resulting in a decline of approximately -8.29% in revenue growth as of 31 July, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Deere's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Deere's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.21% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Deere's ROA stands out, surpassing industry averages. With an impressive ROA of 1.2%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Deere's debt-to-equity ratio stands notably higher than the industry average, reaching 2.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Deere In The Eyes Of 6 Experts

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $60.25, with a high estimate of $68.00 and a low estimate of $55.00. Experiencing a 20.02% decline, the current average is now lower than the previous average price target of $75.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846848_0.png" alt="price target chart" />

<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of PROCEPT BioRobotics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PROCEPT BioRobotics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of PROCEPT BioRobotics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of PROCEPT BioRobotics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRCT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PROCEPT BioRobotics analyst ratings.</a>
<h2>Delving into PROCEPT BioRobotics's Background</h2>
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
<h3>PROCEPT BioRobotics's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining PROCEPT BioRobotics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 48.41% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -24.73%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): PROCEPT BioRobotics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.05%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PROCEPT BioRobotics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.79%, the company may face hurdles in achieving optimal financial performance.
Debt Management: PROCEPT BioRobotics's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 8.87% on an annualized basis producing an average annual return of 21.36%. Currently, Wix.com has a market capitalization of $7.64 billion. 
Buying $100 In WIX: If an investor had bought $100 of WIX stock 10 years ago, it would be worth $692.89 today based on a price of $137.33 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1756846837_0.png" alt="comp_fig" />

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Wix.com Stock In The Last 10 Years

In the latest quarter, 7 analysts provided ratings for Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.86, along with a high estimate of $46.00 and a low estimate of $32.00. Observing a 14.94% increase, the current average has risen from the previous average price target of $31.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846836_0.png" alt="price target chart" />

<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gen Digital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Robert Coolbrith</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$35.00</td>
<td>-</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Gen Digital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Gen Digital compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gen Digital's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Gen Digital's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gen Digital analyst ratings.</a>
<h2>All You Need to Know About Gen Digital</h2>
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
<h3>Financial Insights: Gen Digital</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Gen Digital's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 30.26%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Gen Digital's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 10.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gen Digital's ROE stands out, surpassing industry averages. With an impressive ROE of 5.83%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gen Digital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.85%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Gen Digital's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.75, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Gen Digital Through The Eyes Of 7 Analysts

US Foods Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts have recently evaluated US Foods Holdings and provided 12-month price targets. The average target is $88.33, accompanied by a high estimate of $96.00 and a low estimate of $85.00. This current average reflects an increase of 8.82% from the previous average price target of $81.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846826_0.png" alt="price target chart" />

<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of US Foods Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Mullan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mark Carden</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to US Foods Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of US Foods Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of US Foods Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/USFD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on US Foods Holdings analyst ratings.</a>
<h2>Get to Know US Foods Holdings Better</h2>
US Foods Holding Corp is the U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. It has nearly 250,000 restaurants and foodservice operators with more than 70 locations that provide customers with food offering and a comprehensive suite of e-commerce, technology, and business solutions. The company operates in one business segment in which it markets, sells and distributes fresh, frozen and dry food and non-food products to foodservice customers throughout the U.S.
<h3>US Foods Holdings's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining US Foods Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.84% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: US Foods Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.85%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.63%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.08, US Foods Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About US Foods Holdings Stock

Ratings for Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.5, along with a high estimate of $27.00 and a low estimate of $15.00. Observing a downward trend, the current average is 22.95% lower than the prior average price target of $30.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1756846817_0.png" alt="price target chart" />

<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Eva Fortea Verdejo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xencor compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Xencor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xencor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Xencor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Xencor</h2>
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
<h3>Breaking Down Xencor's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Xencor displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 82.41%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Xencor's net margin excels beyond industry benchmarks, reaching -70.69%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Xencor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.89%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Xencor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.46% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Xencor's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Xencor Stock

Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) shares are hitting new all-time highs in Tuesday&#8217;s after-hours session after a U.S. judge issued a sealed decision in the Google <a href="https://www.benzinga.com/news/topics/25/05/45708275/googles-monopoly-case-takes-a-turn-as-judge-considers-lighter-remedies-amid-rising-competition-from-ai-rivals-like-openai-and-perplexity">online search monopoly case</a>.



See how GOOG shares are currently doing <a href="https://www.benzinga.com/quote/GOOG" target="_blank" rel="noreferrer noopener">here.</a>



What Happened: U.S. District Judge Amit Mehta on Tuesday ruled Google will not be required to divest its Android operating system or sell off Google Chrome, per Reuters.



&#8220;Google will not be required to divest Chrome; nor will the court include a contingent divestiture of the Android operating system in the final judgment &#8230; Plaintiffs overreached in seeking forced divesture of these key assets,&#8221; Mehta wrote in the decision.



The ruling comes after a five-year legal battle between Alphabet and the U.S. in which a district judge ruled last year that Google held an illegal monopoly in its Search business. 



Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares were also moving higher in extended trading, last up about 3.7%, after Mehta ruled that Google will not have to cease payments to Apple for preloading Google products.



The positive rulings appear to be overshadowing a ruling that Google will now have to share data with competitors to create more room for competition in online search. The company previously said it would appeal such a ruling, as Google believes it would allow competitors to reverse-engineer its technology.



GOOG Price Action: <a href="http://benzinga.com/quote/GOOG">Alphabet shares</a> were up 7.57% in after-hours, trading at $228 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/09/47459919/salesforce-q2-earnings-preview-market-expert-says-this-is-the-key-ai-question">Salesforce Q2 Earnings Preview: Market Expert Says This Is The Key AI Question</a></li>
</ul>



Image: Shutterstock.